Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention
Circulation - United States
doi 10.1161/01.cir.100.19.1977
Full Text
Open PDFAbstract
Available in full text
Date
November 9, 1999
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)